<DOC>
	<DOCNO>NCT00846911</DOCNO>
	<brief_summary>The objective global non-interventional study evaluate impact Acute Exacerbation Chronic Bronchitis ( AECB ) patient community well safety effect treatment Moxifloxacin tablet daily life clinical practice . This include data course symptom relief , speed return normal daily life activity well record adverse event . This study perform accordance international guideline like EMEA ( EMEA , EUDRALEX Volume 9A , Pharmacovigilance Medicinal Products Human Use ) well local law .</brief_summary>
	<brief_title>AVANTI - AveloxÂ® Acute Exacerbations chroNic bronchiTIs</brief_title>
	<detailed_description />
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Patients least 35 year age diagnosis Acute Exacerbation Chronic Bronchitis ( AECB ) decision take investigator treat Avelox . Exclusion criterion must read conjunction local product information .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Acute Exacerbation Chronic Bronchitis ( AECB ) patient</keyword>
</DOC>